高盛與普徠仕(TROW.US)達成策略合作 高盛擬斥最多10億美元入股
高盛(GS.US)與普徠仕(TROW.US)達成策略合作,旨在提供一系列多元化的公共和私人市場解決方案,以滿足退休和財富投資者的獨特需求。
此次合作將充分利用兩家公司的優勢,包括各自的投資專長、解決方案導向,以及對中介機構及其客戶需求的深入了解。合作的核心重點是提供一系列財富和退休產品,為個人、財務顧問、計劃發起人和計劃參與者提供進入私人市場的管道。
高盛同時計劃透過一系列公開市場購買方式,投資至多10億美元購入普徠仕普通股,計劃持有至多3.5%股份。
普徠仕隔晚(4日)美股升5.8%收111.52美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.